| Patents for A61P 11 - Drugs for disorders of the respiratory system (87,767) |
|---|
| 02/08/2005 | US6852727 Inhibitors of Janus protein tyrosine kinases (Jak), and as such are useful as immunosuppressants, and in the treatment of diseases including asthma, allergies, autoimmune diseases. |
| 02/08/2005 | US6852726 Such as 1-(4,5-dihydro-1H-imidazol-2-ylmethyl)-3-methanesulfonyl-2-methyl-1H-indole for preventing/treating disorders modulated by alpha-1A/L adrenoceptors such as urinary incontinence and sexual disorders |
| 02/08/2005 | US6852720 Thiazol-2-yl-imine compounds as PDE-7 inhibitors |
| 02/08/2005 | US6852717 Inhibit the release of inflammatory cytokines such as interleukin-1 and tumor necrosis factor; for use in therapy of diseases and pathological conditions involving inflammation such as chronic inflammatory disease |
| 02/08/2005 | US6852518 Glycosyl sulfotransferases GST-4α, GST-4β, and GST-6 |
| 02/08/2005 | CA2151383C Stabilized medicinal aerosol solution formulation |
| 02/03/2005 | WO2005010169A2 High throughput or capillary-based screening for a bioactivity or biomolecule |
| 02/03/2005 | WO2005010007A1 Substituted furochromenes, preparation thereof and their antiinflammatory action |
| 02/03/2005 | WO2005010006A1 Substituted furochromene compounds of antiinflammatory action |
| 02/03/2005 | WO2005009995A1 Nicotinamide derivatives useful as pde4 inhibitors |
| 02/03/2005 | WO2005009994A1 Nicotinamide derivatives useful as pde4 inhibitors |
| 02/03/2005 | WO2005009992A1 Cyclohexanecarboxylic acid compound |
| 02/03/2005 | WO2005009989A1 Nicotinamide derivatives useful as pde4 inhibitors |
| 02/03/2005 | WO2005009969A1 Aminoquinoline derivatives and their use as adenosine a3 ligands |
| 02/03/2005 | WO2005009968A1 Quinoline derivates and their use in therapy |
| 02/03/2005 | WO2005009445A1 A1 adenosine receptor antagonists |
| 02/03/2005 | WO2005009427A1 Curative medicine for allergosis |
| 02/03/2005 | WO2005009343A2 A1 adenosine receptor antogonists |
| 02/03/2005 | WO2004106279A3 CRYSTALLINE FORM OF β2 ADRENERGIC RECEPTOR AGONIST |
| 02/03/2005 | WO2004100863A3 Composition for preventing and treatment of asthma comprising alpha-lipoic acid as an effective component |
| 02/03/2005 | WO2003094859A3 Epha2 monoclonal antibodies and methods of use thereof |
| 02/03/2005 | WO2003062390A3 Compositions and methods for the modulation of sphingolipid metabolism and/or signaling |
| 02/03/2005 | WO2002096360A3 Single amino acid based compounds for counteracting effects of reactive oxygen species and free radicals |
| 02/03/2005 | US20050027121 Heterocyclic carboxy amines such as (2R)-1-[3,5-Bis(trifluoromethyl)benzoyl]-4-[4-((3S)-3-ethylmorpholino)-2-butynyl]-2-[(1H-indol-3-yl)methyl]piperazine, used as substance P and neurokinin antagonist for prophylaxis of diseases |
| 02/03/2005 | US20050027114 Methods and materials relating to cd84-like polypeptides and polynucleotides |
| 02/03/2005 | US20050027103 Matrix protein for use diagnosis, treatment, and prevention of viral infections, cell proliferative and neurological disorders |
| 02/03/2005 | US20050027017 Rhinologically active substances |
| 02/03/2005 | US20050027009 New derivatives of N-(iminomethyl)amines, their preparation, their use as medicaments and the pharmaceutical compositions containing them |
| 02/03/2005 | US20050026990 N-[(3S)-1-hydroxy-2-oxopyrrolidinyl]-N-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-4-sulfonamide or derivatives to treat Respiratory system disorders; arthritis, and bone disorders |
| 02/03/2005 | US20050026988 Cyclopenta'b! indole derivatives as spla inhibitors |
| 02/03/2005 | US20050026967 Inhibitors of c-jun N terminal kinases (JNK) and other protein kinases |
| 02/03/2005 | US20050026965 Pharmaceutical uses and synthesis of nicotinanilide-N-oxides |
| 02/03/2005 | US20050026942 Chemokine receptor binding heterocyclic compounds |
| 02/03/2005 | US20050026941 preferential inhibitors of cyclic guanosine 3',5'-monophosphate specific phosphodiesterase used for prophylaxis of erectile dysfunction and cardiovascular disorders |
| 02/03/2005 | US20050026908 Can bind to Prostaglandin E2 receptors, especially, EP3 receptor and/or EP4 receptor and show antagonizing activity, and may be useful for prevention and/or treatment of disease, for example, pain, allergy, Alzheimer's disease, cancer |
| 02/03/2005 | US20050026906 Such as N-4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-methyl-isonicotinamide; for control or prevention of illnesses based on the modulation of the adenosine system, such as Alzheimer's disease, Parkinson's disease, neuroprotection, schizophrenia, anxiety, pain |
| 02/03/2005 | US20050026904 Cathepsin S, K, F, L and B reversible inhibitory amidino and guanidino peptidyl compounds useful for treating autoimmune diseases, rheumatoid arthritis, multiple sclerosis, asthma and osteoporosis |
| 02/03/2005 | US20050026901 Antihistaminic spiro compounds |
| 02/03/2005 | US20050026888 Formulation containing anti-inflammatory androstane derivatives |
| 02/03/2005 | US20050026875 Treating bacterial, viral, or fungal infections, cancer, a lung injury, an eye disorder, neurological disorder or stroke |
| 02/03/2005 | US20050026858 Modified nucleotides for immunotherapy; induce immunology response; consisting of nucleoside methylphosphonate and 2'-O-methyl-ribonucleoside groups |
| 02/03/2005 | US20050025751 Increased or reduced expression of tumor necrosis factors or interleukins; antiinflammatory agents; autoimmune diseases |
| 02/03/2005 | CA2770493A1 Cyclohexanecarboxylic acid compound |
| 02/03/2005 | CA2546481A1 Substituted furochromenes, preparation thereof and their antiinflammatory action |
| 02/03/2005 | CA2533663A1 Nicotinamide derivatives useful as pde4 inhibitors |
| 02/03/2005 | CA2533624A1 Nicotinamide derivatives useful as pde4 inhibitors |
| 02/03/2005 | CA2533584A1 Substituted furochromene compounds of antiinflammatory action |
| 02/03/2005 | CA2533402A1 A1 adenosine receptor antagonists |
| 02/03/2005 | CA2532249A1 Nicotinamide derivatives useful as pde4 inhibitors |
| 02/03/2005 | CA2532154A1 Quinoline derivates and their use in therapy |
| 02/03/2005 | CA2528586A1 Cyclohexanecarboxylic acid compound |
| 02/02/2005 | EP1502916A1 Piperidine derivatives having ccr3 antagonism |
| 02/02/2005 | EP1502600A1 Use of botulinum toxin for treating smooth muscle disorders |
| 02/02/2005 | EP1502593A1 The use of Stanozolol for the preparation of anti-inflammatory and anti-degenerative drugs |
| 02/02/2005 | EP1501948A1 A dna enzyme to inhibit plasminogen activator inhibitor-1 |
| 02/02/2005 | EP1501834A1 Triaryl-oxy-aryl-spiro-pyrimidine-2, 4, 6-trione metalloproteinase inhibitors |
| 02/02/2005 | EP1501833A1 N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| 02/02/2005 | EP1501827A2 Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acid and their use as protease inhibitors |
| 02/02/2005 | EP1501826A2 Substituted indoles as alpha-1 agonists |
| 02/02/2005 | EP1501809A1 Triazole derivatives as tachykinin receptor antagonists |
| 02/02/2005 | EP1501808A1 Tachykinin receptor antagonists |
| 02/02/2005 | EP1501807A1 Sulfonylquinoxalone acetamide derivatives and related compounds as bradykinin antagonists |
| 02/02/2005 | EP1501803A2 Tetrahydropyranyl cyclopentyl tetrahydroisoquinoline modulators of chemokine receptor activity |
| 02/02/2005 | EP1501801A1 2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them and their uses as vla-4 inhibitors |
| 02/02/2005 | EP1501800A1 Bombesin antagonists |
| 02/02/2005 | EP1501797A1 3-substituted amino-1h-indole-2-carboxylic acid and 3-substituted amino-benzo[b]thiophene-2-carboxylic acid derivatives as interleukin-4 gene expression inhibitors |
| 02/02/2005 | EP1501796A1 3-substituted amino-1h-indole-2-carboxylic acid and 3-substituted amino-benzo[b]thiophene-2-carboxylic acid derivatives as interleukin-4 gene expression inhibitors |
| 02/02/2005 | EP1501787A1 N-biphenylmethyl aminocycloalkanecarboxamide derivatives with a substiituent on the methyl useful as bradykinin antagonists |
| 02/02/2005 | EP1501605A1 Novel use of guanylate cyclase activators for the treatment of respiratory insufficiency |
| 02/02/2005 | EP1501545A2 Use of tnfalpha antibodies and another drug |
| 02/02/2005 | EP1501523A1 Carbon monoxide as a biomarker and therapeutic agent |
| 02/02/2005 | EP1501515A1 Triaryl-oxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| 02/02/2005 | EP1501514A2 Protein kinase modulators and methods of use |
| 02/02/2005 | EP1501508A1 Inhibitors of histone deacetylase |
| 02/02/2005 | EP1501504A1 1-substituted imidazole derivatives as nos inhibitors |
| 02/02/2005 | EP1501492A1 ANTI- i RHINOVIRUS /i ACTIVE AGENTS |
| 02/02/2005 | EP1501483A2 Particulate materials |
| 02/02/2005 | EP1501479A1 Capsules for dry powder inhalers and methods of making and using same |
| 02/02/2005 | EP1501467A2 Heterocyclo inhibitors of potassium channel function |
| 02/02/2005 | EP1440161A4 7118, a human arginine n-methyltransferase family member and uses therefor |
| 02/02/2005 | EP1303506B1 6-heteroarylphenanthridines |
| 02/02/2005 | EP1221490B1 Recombinant adenoviral vectors and their utilization in the treatment of liver cirrhosis |
| 02/02/2005 | EP1124779B1 Vitamin d analogues |
| 02/02/2005 | EP1025079B1 $g(a)-ARYL-$i(N)-ALKYLNITRONES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
| 02/02/2005 | EP1011688B1 Use of uridine 5'-diphosphate and analogs thereof for the treatment of lung diseases |
| 02/02/2005 | EP1007017B1 New formulation for inhalation having a poured bulk density of 0.28 to 0.38 g/ml, a process for preparing the formulation and the use thereof |
| 02/02/2005 | EP0912575B1 Processes for the synthesis of chemical compounds having pde-iv inhibitory activity |
| 02/02/2005 | EP0851769B1 Gene therapy using ovine adenoviral vectors |
| 02/02/2005 | CN1575334A Pathogen for bacterial poultry disease |
| 02/02/2005 | CN1575291A Derivatives of 4-(thio- or selenoxanthene-9-ylidene)-piperidine or acridine and its use as a selective 5-ht2b receptor antagonist |
| 02/02/2005 | CN1575290A Pyrimidine derivatives and pharmaceutical compositions containing that compounds |
| 02/02/2005 | CN1575283A Piperazine derivatives with CCRI receptor antagonist activity |
| 02/02/2005 | CN1575279A Substituted thioacetamides |
| 02/02/2005 | CN1575273A 3, 4-di-substituted cyclobutene-1, 2-diones as CXC-chemokine receptor antagonists |
| 02/02/2005 | CN1575182A Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate |
| 02/02/2005 | CN1575179A Combination product comprising melagatran and dexamethasone |
| 02/02/2005 | CN1575177A Cxcr3 antagonists |
| 02/02/2005 | CN1575175A Drug formulation having improved oral tolerability |
| 02/02/2005 | CN1575174A Pharmaceutically active isoindoline derivatives |
| 02/02/2005 | CN1575173A Macrolides containing pharmaceutical compositions |